Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
Condition: BRAF V600E-mutant Metastatic Colorectal Cancer · Sponsor: Pierre Fabre Medicament
About this study
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (45)
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| PC dba West Cancer Center | Germantown, Tennessee, United States | — |
| Krankenhaus der Barmherzigen Brüder | Vienna, Austria | — |
| UZ Gent, Gastro-Enterology | Ghent, East Flanders, Belgium | — |
| Trial DIO, UZ Gasthuisberg | Leuven, Flemish Brabant, Belgium | — |
| Cliniques universitaires Saint-Luc | Brussels, Belgium | — |
| ICM- VAL d 'Aurelle | Montpellier, Cedex 5, France | — |
| Hôpital Morvan CHRU de Brest Institut de cancérologie et d'hematologie | Brest, France | — |
| AP-HM CHU Timone | Marseille, France | — |
| Hôpital Cochin Gastroenterology | Paris, France | — |
| Hôpital Europeen Georges Pompidou | Paris, France | — |
| Hôpital Saint Antoine | Paris, France | — |
+ 33 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03693170